RecruitingAdvanced Solid TumorMetastatic Solid TumorEndometrial Cancer
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
8 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients with microsatellite instability high (MSI-H) or DNA mismatch repair deficiency (dMMR) solid tumors.
Sponsor: MOMA Therapeutics
You may qualify if…
- ✓ 1. Age ≥ 18 years
- ✓ 2. Participants have unresectable advanced or metastatic solid tumors with MSI-H or dMMR alterations and histologically confirmed disease. Participants must have previously received and progressed on an anti-PD-(L)1-based regimen, unless ineligible or in a region without access to anti-PD-(L)1 therapies
- ✓ 3. Have at least 1 lesion at baseline (measurable or non-measurable) suitable for repeat imaging evaluation by RECIST and/or PCWG-3
- ✓ 4. ECOG PS ≤ 2
- ✓ 5. Fully recovered from clinically relevant effects of prior therapy, radiotherapy, and/or surgery \*\*hormonal therapy allowed. Palliative radiotherapy allowed
- ✓ 6. Adequate organ function per local labs
- ✓ 7. Comply with contraception requirements
- ✓ 8. Written informed consent must be obtained according to local guidelines
You may not qualify if…
- ✕ 1. Known Werner Syndrome
- ✕ 2. Active prior or concurrent advanced-stage malignancy (some exceptions allowed including early-stage cancers)
- ✕ 3. Clinically relevant cardiovascular disease
- ✕ 4. Known CNS metastasis associated with progressive neurological symptoms (stable doses of corticosteroids allowed)
- ✕ 5. Known active uncontrolled infection
- ✕ 6. Known allergy, hypersensitivity, and/or intolerance to MOMA-341
- ✕ 7. Impaired GI function that may impact absorption
- ✕ 8. Patient is pregnant or breastfeeding
Where it's recruiting
Arizona
Phoenix
California
San Diego
Florida
Tampa
Michigan
Detroit
Missouri
St Louis
North Carolina
Raleigh
Oregon
Portland
Texas
Dallas · Houston
Source: ClinicalTrials.gov · NCT06974110 · last updated 2026-07-23